PharmAust Completes Share Purchase Plan
Released
Released
Announcement PDF
PHARMAUST COMPLETES SHARE PURCHASE PLAN
Highlights:
Successful completion of Share Purchase Plan (SPP) raising $7.8m
Demand was significantly in excess of the initial $2m sought
$17.8m in combined proceeds from the SPP and Placement significantly reduces future
funding requirements to execute the HEALEY ALS Platform Trial
Exceptional support from shareholders on the same terms as the recently completed
$10m institutional and sophisticated investor Placement
Potential additional nondilutive funds from R&D Tax Incentive and grants this H2 CY2024
24 July 2024 – Melbourne, Australia: PharmAust Limited (ASX:PAA) (PharmAust or the Company)
is pleased to announce the successful completion of its Share Purchase Plan (“SPP”) which closed on
Friday, 19 July 2024.
Demand for the SPP was significantly in excess of the initial target of $2.0 million, closing with $7.8
million in applications being accepted. Given the strong shareholder support and to provide all
shareholders with the opportunity to participate on the same terms as the Placement, the Board has
exercised its discretion under the terms of the SPP and has accepted all valid applications made under
the SPP. The additional funds raised through the SPP provides PharmAust significant funding,
strengthens its balance sheet and minimises any future funding requirements.
The SPP complements the Company’s recently announced placement to institutional and sophisticated
investors, which raised $10 million (before costs) at an issue price of $0.19 per share. The Placement
and SPP combined together, has raised a total of approximately $17.8 million (before costs).
PharmAust Chairman Sergio Duchini commented: “On behalf of the Board, I would like to extend a
sincere thank you to our loyal shareholders who have supported our Share Purchase Plan. The strong
participation resulted in the SPP being significantly in demand. This endorsement from our shareholders
strengthens our commitment to our refreshed strategic direction to advance the development of
monepantel for ALS and other neurodegenerative conditions. We are grateful for the ongoing support
from our shareholders.”
“Coupled with the recent successful $10 million Placement announced on 21 June 2024, and the
partnership with the HEALEY ALS Platform Trial announced on 15 July 2024, these events mark a
significant validation step in our efforts to accelerate the development of monepantel as a viable
treatment for ALS. PharmAust is well-positioned to finalise preparations towards commencing a pivotal
registration study for monepantel for the treatment of amyotrophic lateral sclerosis.
“With many important milestones on the horizon, including the commencement in the HEALEY ALS
Platform Trial in H2 CY2024, we look forward to keeping shareholders up to date on our progress.
PharmAust would like to thank all our shareholders for their continued support.”
A total of 41,095,506 new fully paid ordinary shares will be issued on 25 July 2024, to SPP participants
pursuant to ASX Listing Rule 7.2, Exception 5, with trading on ASX expected to commence on 26 July
2024. Dispatch of holding statements is expected to occur on 29 July 2024.
PharmAust Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205
Tel: +61 3 9692 7222
www.pharmaust.com
Funds raised under the SPP will be used to finalise preparations for the HEALEY ALS Platform Trial,
GMP manufacturing, preclinical models for other neurodegenerative diseases, regulatory filings,
working capital and offer costs.
This announcement is authorised for release by the Board of Directors of PharmAust Limited.
For further information, please contact:
Dr Michael Thurn
Managing Director
investorenquiries@pharmaust.com
P +61 (3) 9692 7222
W www.pharmaust.com
Media:
Catherine Strong
Sodali & Co
catherine.strong@sodali.com
P 0406 759 268
PharmAust Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205
Tel: +61 3 9692 7222
www.pharmaust.com
About PharmAust Limited:
PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage
biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused
on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of
motor neurone disease (MND) and affects both upper and lower motor neurons.
MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and
proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning
process”, where toxic proteins are broken down into macromolecules to be reused. This autophagic process
is disrupted in most neurodegenerative diseases, including ALS.
The company recently announced positive top-line results for its Phase 1 MEND study in participants with
ALS. MPL has been selected for inclusion in the HEALEY ALS Platform Trial and anticipates commencing
enrolment in Q4 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US
Food and Drug Administration for monepantel for the treatment of ALS in 2026.
In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a
forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.1
1
https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market
PharmAust Investor Hub:
We encourage you to utilise our Investor Hub for any enquiries regarding
this announcement or other aspects concerning PharmAust. This platform
offers an opportunity to submit questions, share comments, and view video
summaries of key announcements.
Access the investor hub by scanning the QR code or visiting:
https://investorhub.pharmaust.com/
PharmAust Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205
Tel: +61 3 9692 7222
www.pharmaust.com
Share your feedback
Discover